

Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss whatsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

INSIDE INFORMATION ANNOUNCEMENT

This announcement is made by Shenzhen Heparlink Pharmaceutical Group Co., Ltd. (the **Company**, together with its subsidiaries, the **Group**), in accordance with the Inside Information Provisions of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (**Listing Rules**).

The Board of Directors (the **Directors**) of the Company (the **Board**) is hereby notified of the Shareholders (the **Shareholders**) and the Italian Techdow Pharma S.R.L., a wholly owned subsidiary of the Company (**Techdow Italy**), is expected to have been defaulted by a criminal decree issued by the Italian judicial authorities on 11.7.2014 (the **Incident**). The Company has filed the Incident with the Italian judicial authorities. The Italian authorities have filed a criminal investigation in the case. As a result, the Company is still conducting the investigation and taking effective measures.

The management of the Company has implemented the Board's decision to take the necessary measures and the directors of the Board of the Incident, a decision to take the necessary measures. The management of the Company has filed a criminal investigation in the Incident case. The Company's management is still conducting the investigation and taking effective measures.

